Cargando…

Pharmacological targeting of TNS3 with histone deacetylase inhibitor as a therapeutic strategy in esophageal squamous cell carcinoma

Histone acetylation which regulates about 2-10% of genes has been demonstrated to be involved in tumorigenesis of esophageal squamous cell carcinoma (ESCC). In this study, we investigated the treatment response of ESCC to selective histone deacetylase inhibitor (HDACi) LMK-235 and potential biomarke...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Yang, Xiang, Zheng, Yang, Huiyu, Khan, Suliman, Li, Ruizhe, Zhou, Siran, Ullah, Saif, Zhang, Jiyu, Liu, Bingrong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221360/ https://www.ncbi.nlm.nih.gov/pubmed/34047714 http://dx.doi.org/10.18632/aging.203091

Ejemplares similares

Super-enhancers in esophageal carcinoma: Transcriptional addictions and therapeutic strategies
por: Shi, Yang, et al.
Publicado: (2022)

Immunohistochemical Analysis of the Expression of Adhesion Proteins: TNS1, TNS2 and TNS3 in Correlation with Clinicopathological Parameters in Gastric Cancer
por: Nizioł, Marcin, et al.
Publicado: (2021)

Selective synergistic anticancer effects of cisplatin and oridonin against human p53-mutant esophageal squamous carcinoma cells
por: Yang, Huiyu, et al.
Publicado: (2021)

Multifaceted Influence of Histone Deacetylases on DNA Damage Repair: Implications for Hepatocellular Carcinoma
por: Du, Gan, et al.
Publicado: (2023)

Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Abnormal TNS3 gene methylation in patients with congenital scoliosis
por: Wu, YuanTao, et al.
Publicado: (2022)

Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment
por: Schizas, Dimitrios, et al.
Publicado: (2018)

Histone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review
por: Chen, Xiaona, et al.
Publicado: (2020)

Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF1
por: Yang, Yang, et al.
Publicado: (2022)

Histone Deacetylase 3: A Potential Therapeutic Target for Atherosclerosis
por: Jiang, Li-Ping, et al.
Publicado: (2022)

Histone Deacetylase Functions in Gastric Cancer: Therapeutic Target?
por: Badie, Amandine, et al.
Publicado: (2022)

Patho-epigenetics: histone deacetylases as targets of pathogens and therapeutics
por: Schator, Daniel, et al.
Publicado: (2021)

The miR-1224-5p/TNS4/EGFR axis inhibits tumour progression in oesophageal squamous cell carcinoma
por: Shi, Zhi-Zhou, et al.
Publicado: (2020)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability
por: Milazzo, Giorgio, et al.
Publicado: (2020)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Stenotrophomonas maltophilia promotes lung adenocarcinoma progression by upregulating histone deacetylase 5
por: Shen, Jiyu, et al.
Publicado: (2023)

Histone deacetylase 10 structure and molecular function as a polyamine deacetylase
por: Hai, Yang, et al.
Publicado: (2017)

High fidelity simulation of the endoscopic transsphenoidal approach: Validation of the UpSurgeOn TNS Box
por: Newall, Nicola, et al.
Publicado: (2022)

Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors
por: Miller, Claudia P., et al.
Publicado: (2011)

The class II histone deacetylases as therapeutic targets for Parkinson’s disease
por: Mazzocchi, Martina, et al.
Publicado: (2020)

Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors
por: Han, Yu, et al.
Publicado: (2022)

Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular Dystrophies
por: Sandonà, Martina, et al.
Publicado: (2023)

A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma
por: Selim, Omar, et al.
Publicado: (2023)

Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma
por: Jaime-Ramirez, Alena C., et al.
Publicado: (2017)

Impact of histone deacetylase 1 and metastasis-associated gene 1 expression in esophageal carcinogenesis
por: MIYASHITA, TOMOHARU, et al.
Publicado: (2014)

The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington’s Disease Mice
por: Jia, Haiqun, et al.
Publicado: (2016)

Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies
por: Yang, Jia, et al.
Publicado: (2020)

MLL3 suppresses tumorigenesis through regulating TNS3 enhancer activity
por: Zheng, Jun-Yi, et al.
Publicado: (2021)

TNS1: Emerging Insights into Its Domain Function, Biological Roles, and Tumors
por: Wang, Zhihui, et al.
Publicado: (2022)

Emerging roles of histone deacetylases in adaptive thermogenesis
por: Zhou, Ruonan, et al.
Publicado: (2023)

Histone deacetylase 6 expression in metastatic lymph nodes is a valuable prognostic marker for resected node-positive esophageal squamous cell cancer
por: Xie, Xuan, et al.
Publicado: (2018)

Chemical Phylogenetics of Histone Deacetylases
por: Bradner, James E., et al.
Publicado: (2010)

Histone deacetylases in viral infections
por: Herbein, Georges, et al.
Publicado: (2010)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone deacetylase signaling in cardioprotection
por: Lehmann, Lorenz H., et al.
Publicado: (2013)

Next-generation of selective histone deacetylase inhibitors
por: Yang, Feifei, et al.
Publicado: (2019)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6ne2l9kbapq9g28hc22ihho2fh